Aurora Cannabis Inc. produces and sells cannabis and cannabis-derived products in Canada and internationally. The company boasts a strong gross margin of 52.7% and a solid liquidity position with a current ratio of 5.36, indicating good short-term financial health. However, concerns arise from its negative net margin of -6.0% and low profitability metrics, such as an EBITDA margin of just 1.2%. Despite high margins, the market cap of $353.27M suggests potential undervaluation, reflecting investor caution in the volatile cannabis sector.
Loading financial metrics...
Gross profit margin declined from 55.1% to 40.7% year-over-year, suggesting pricing pressure or rising input costs are squeezing profitability.
Company posted a loss of $-72.6M over the last year, representing 20.7% of revenue.
Exceptional revenue growth of 34.7% YoY demonstrates strong market demand and competitive positioning.
Fortress balance sheet: cash covers total debt 4.4×, providing significant financial flexibility.
Excellent liquidity with current ratio of 5.4x ensures operational stability.
Low debt-to-revenue ratio of 6.5% indicates conservative financial management.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2027-Q1 (June 30, 2026)